HVTN 144 is a clinical study to check the safety and immune response of a new HIV vaccine on 84 healthy adults aged 18-55 who do not have HIV. The vaccine uses something called the N332-GT5 gp140 HIV envelope trimer, which is a part of the virus used to teach the immune system to fight against HIV. This is mixed with a special ingredient, called SMNP, to boost the body's response. The study tests different ways and doses of giving the vaccine to find the safest and most effective method. Volunteers will receive the vaccine either in the muscle (intramuscular or IM) or under the skin (subcutaneous or SC) over a period of 22 months, including follow-ups and safety checks. Before joining, participants must meet specific health criteria to ensure they are a good fit for the study.

• The study lasts 22 months, including 8 months for enrollment and check-ups.
• Participants receive 2 to 6 vaccinations depending on the group they are in.
• Volunteers must be in good health and agree to follow study rules, including not joining other studies.